Physician profile
Ellen Ann Maurus
NPI 1316673452
$1,081.63
in general payments reported to CMS, 2019-2025
15 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $23.55 · 2023: $236 · 2024: $467 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,058.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $139.14 | 2022-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $113.55 | 2023-2025 | Zepbound, Mounjaro, Kisunla |
| Astrazeneca Pharmaceuticals LP | $101.36 | 2023-2024 | Bevespi Aerosphere, Airsupra |
| Abbvie INC. | $100.75 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $90.80 | 2023-2025 | Capvaxive, Gardasil 9, M-M-R II |
| Amgen INC. | $90.54 | 2024-2025 | Krystexxa, Repatha, Repatha |
| Sumitomo Pharma America, INC. | $90.12 | 2024-2025 | Gemtesa |
| Pfizer INC. | $84.35 | 2024-2025 | |
| Exact Sciences Corporation | $84.25 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $52.45 | 2023-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.92 | 2023 | Xifaxan |
| Glaxosmithkline, LLC. | $27.19 | 2024 | Trelegy Ellipta |
| Ardelyx, INC. | $23.44 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $19.91 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.86 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Maurus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.